Romain Guyon Explores Single-Dose Rabies Vaccines
Romain Guyon, Ph.D. at the University of Oxford, was recognized with the 2022 Michelson Prizes: Next Generation Grant for his work developing a single-dose vaccination against rabies.
Michelson Next Generation Grants, which are awarded annually to researchers focused on human immunology, vaccine discovery, and immunotherapy, will provide $150,000 to further Guyon's research in the field.
His innovative approach uses biodegradable particles to delay the release of a booster vaccine, creating a single injection solution to replace the current multi-injection regimen, which is often difficult to comply with in developing countries. Guyon's work has the potential to improve immunization rates against rabies and reduce the logistical and cost burdens associated with multiple vaccine doses.
Romain Guyon in his lab at The Jenner Institute (University of Oxford).
About Michelson Prizes:
The Michelson Prizes: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases.
The 2023 Michelson Prizes will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development.
For more information about the prizes, please visit https://www.michelsonmedicalresearch.org/michelson-prizes-next-generation.